Dashboard

Regeneron Pharmaceuticals, Inc.

REGNNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$81B

Price$801.8252w $483.07 – $852.03

Conviction4/ 5

Revenue (TTM)$15.5B

Revenue growth YoY+9.3%

P/E (trailing)18.7

Gross margin84.9%

Operating margin25.6%

Net margin27.9%

52w price change+63.4%

Next earningsOct 27, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

Sep 3
Ownership changeSEC
SEC Form 4 insider transaction report filed.
Sep 3
Ownership changeSEC
Form 4 filing reporting change in beneficial ownership.
Aug 21
Ownership changeSEC
SEC Form 4 filing for change in beneficial ownership at Regeneron Pharmaceuticals.
Aug 20
Ownership changeSEC
Form 4 insider transaction filing dated 2026-08-20.
Aug 12
Ownership changeSEC
SEC Form 4 insider transaction filing dated 2026-08-12.
Aug 12
Ownership changeSEC
SEC Form 4 insider transaction filing.
Jul 30
Financial resultsSEC
8-K filed with items 2.02 and 9.01 disclosing financial results.
Jul 7
Ownership changeSEC
Form 4 insider ownership filing
Jul 6
Financial resultsSEC
Regeneron filed Form 8-K item 2.02 on results of operations and financial condition.
Jun 17
OtherSEC
Regeneron filed Form 8-K (item 5.07) disclosing results of matters submitted to security holder vote.
Jun 3
Trial initiationClinicalTrials.gov
Viz.ai trial NCT07118306 (COPD Exacerbation Follow Up) status updated to recruiting
May 15
Trial initiationClinicalTrials.gov
Phase 2 platform trial (NCT07058012) recruiting for cemiplimab monotherapy or + fianlimab in colorectal cancer with MRD post-surgery/chemotherapy
May 4
OtherSEC
SEC Form 4 insider ownership filing

Not financial advice — research and opinion only. Disclosures